Investors / Singapore / ClavystBio
ClavystBio
Venture capital · Singapore, Singapore · Asia Pacific
ClavystBio is a life sciences venture capital firm that invests in biotechnology and medical technology companies. It leads seed and Series A rounds and also partners with founders on company formation, supporting portfolio companies as they scale internationally.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechnologymedical technologytherapeuticshealthcare
Your fit with ClavystBio
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsClavystBio lists 13 checked portfolio companies on its own site and is named in 6 funding rounds, 3 of them as lead. Its most frequent entry is Series B, 33% of the companies with a known first round. Its largest themes are Healthcare & Biotech (86%), Consumer (7%) and Industrial & Manufacturing (7%). 55% of its companies are based in United States. It invests most often alongside F-Prime Capital, Frazier Life Sciences and Pureos Bioventures.
Counts come from funding rounds that name ClavystBio, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not ClavystBio's whole history. Rounds on record name 6 companies; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 17% |
| Series A | 17% |
| Series B | 33% |
| Growth | 33% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 1 |
| '26 | 4 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 57th | 17% of entries at pre-seed or seed |
| Evidence | 97th | 31% of companies confirmed by a round |
| Sector focus | 94th | 86% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| F-Prime Capital | 2 |
| Frazier Life Sciences | 2 |
| Pureos Bioventures | 2 |
| AMED Ventures | 1 |
| ARCH Venture Partners | 1 |
| Altium Capital | 1 |
| Alumni Ventures | 1 |
| Angelini Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 86% | 15% |
| Consumer | 7% | 3% |
| Industrial & Manufacturing | 7% | 7% |
Co-investor network
who it backs companies with, and who they back togetherCompare ClavystBio head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with ClavystBio| Date | Company | Stage |
|---|---|---|
| 5 Oct 2026 | Series C+ | |
| 29 Jun 2026 | Series C+ Led | |
| 25 Jun 2026 | Series B | |
| 2 Oct 2025 | Seed Led | |
| 6 May 2025 | Series B |
Round details for ClavystBio
Amounts, full round histories and every co-investor in ClavystBio's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 65LAB accelerates the drug discovery pathway and new company formation by bringing together the expertise of global partners | Healthcare & Biotech | Portfolio page | ||
| Automera is pioneering a new frontier in autophagy-driven degradation through computational chemistry, artificial intelligence, and quantum molecular dynamics. | Healthcare & Biotech | Portfolio page | ||
| Biobot Surgical develops and provides robotic solutions for prostate disease management | Healthcare & Biotech | Jun 2026Series C+ | Funding round | |
| Callio Therapeutics is a global, clinical-stage biotechnology company developing dual-payload antibody-drug conjugates (ADCs) to address the key limitation of current therapies, resistance. | Healthcare & Biotech | Portfolio page | ||
| Cirrus Therapeutics is developing therapies to treat age-related macular degeneration (AMD) by leveraging ocular immunology | Healthcare & Biotech | Oct 2025Seed | Page + round | |
| Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. | Healthcare & Biotech | Portfolio page | ||
| Hummingbird Bioscience is developing a pipeline of next-generation antibody-based therapeutics, including ADCs, for patients who do not respond to current treatments. | Healthcare & Biotech | Portfolio page | ||
| Leyden Labs is a clinical-stage biotechnology company that is fundamentally changing how we protect people from airborne viruses by building a new class of Mucosal Protection Products | Healthcare & Biotech | Jun 2026Series B | Page + round | |
| Nuevocor develops and tests medicines for treating cardiomyopathies | Healthcare & Biotech | May 2025Series B | Page + round | |
| The company navigates evolutionary data to translate extreme biological adaptations into first-in-class medicines | Healthcare & Biotech | Portfolio page | ||
| Quilt manufactures and installs ductless heat pump systems for homes. | ConsumerIndustrial & Manufacturing | Portfolio page | ||
| Rejoni is involved in uterine health | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides a treatment for benign prostatic hyperplasia (BPH) | Healthcare & Biotech | Oct 2026Series C+ | Page + round |
About this data
site last read 5 Nov 2026- Site
- clavystbio.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 6 May 2025
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get ClavystBio's profile as data
Pull ClavystBio's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/clavystbio.com
# also
GET /v1/firms/clavystbio.com/portfolio
GET /v1/firms/clavystbio.com/coinvestors
GET /v1/firms/clavystbio.com/news